<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156398">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918592</url>
  </required_header>
  <id_info>
    <org_study_id>ACEBIB</org_study_id>
    <nct_id>NCT01918592</nct_id>
  </id_info>
  <brief_title>PET/MRI and Biomarkers in Bladder Cancer</brief_title>
  <acronym>ACEBIB</acronym>
  <official_title>PET/MRI and Biomarkers in Clinical Staging of Bladder Cancer and in the Estimation of Neoadjuvant Chemotherapy Response Prior to Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscle invasive bladder cancer is an aggressive malignancy. Currently the investigators lack
      accurate imaging technologies in clinical staging and estimation of response to neoadjuvant
      chemotherapy as well as prognostic biomarkers.

      In the current study novel imaging modality (MRI/PET) is utilized to stage bladder cancer
      prior to transurethral resection of bladder-tumor and after neoadjuvant chemotherapy. Also
      prognostic biomarkers are studied from TUR-BT tissues, blood and urine to estimate response
      to neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>staging accuracy of PET/MRI in bladder cancer</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy of PET/MRI to stage newly diagnosed bladder cancer. MRI/PET staging results is compared to pathology report of TUR-BT and cystectomy specimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy of PET/MRI to estimate response to neoadjuvant chemotherapy</measure>
    <time_frame>3 mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy of PET/MRI to estimate response to neoadjuvant chemotherapy prior to radical cystectomy. MRI/PET results is compared to pathology report of cystectomy specimen.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Accuracy of prognostic biomarkers to estimate response to neoadjuvant chemotherapy.</measure>
    <time_frame>6 mo</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy of tissue, blood and urine based biomarkers to estimate response to neoadjuvant chemotherapy is estimated</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>MRI/PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI/acetate-PET imaging</intervention_name>
    <arm_group_label>MRI/PET</arm_group_label>
    <other_name>Philips Ingenuity PET/MR device</other_name>
    <other_name>11C-acetate as PET-tracer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  invasive or locally advanced bladder cancer based on cystoscopic evaluation

          -  Age: 18 to 85 years old

          -  Language spoken: Finnish or Swedish

          -  Mental status: Patients must be able to understand the meaning of the study

          -  Informed consent: The patient must sign the appropriate Ethical Committee (EC)
             approved informed consent documents in the presence of the designated staff

        Exclusion Criteria:

          -  Prior medical history: Patient must have no history of serious cardiovascular, liver
             or kidney disease

          -  Infections: Patient must not have an uncontrolled serious infection

          -  Contraindications for MRI (cardiac pacemaker, intracranial clips etc)

          -  Patient refusing radical cystectomy or chemotherapy

          -  Intravesical Bacillus Calmette-Guerin instillations within 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter J. Bostrom, MD, PhD</last_name>
    <phone>+358-2-3135925</phone>
    <email>peter.bostrom@tyks.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilmari Koskinen, MD</last_name>
      <email>ilmari.koskinen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Ilmari Koskinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Kotsar, MD</last_name>
      <email>andres.kotsar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andres Kotsar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Bostrom, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Bostrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Bostr√∂m</investigator_full_name>
    <investigator_title>chief, department of urology</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>radical cystectomy</keyword>
  <keyword>lymphadenectomy</keyword>
  <keyword>biomarker</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
